MarketCap
Facebook
X
Telegram
Cue Biopharma Market Cap | CUE
As of October 25, 2026 Cue Biopharma has a market cap of $ 1.77 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Cue Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 M | 51.3 M | 86.5 M | 108 M | 354 M | 388 M | 337 M | 101 M | 311 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 388 M | 29.4 M | 196 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B |  USA |
 |
Tyme Technologies
TYME
|
41.5 M | - | 8.07 % | $ 54 M | USA |
 |
Codiak BioSciences
CDAK
|
243 M | - | -55.98 % | $ 2.15 M | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
114 M | $ 5.17 | 0.78 % | $ 44 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Sage Therapeutics
SAGE
|
434 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.36 B | - | - | $ 1.62 B |  Israel |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
25.2 B | - | - | $ 26.6 B |  Irlanda |
 |
Equillium
EQ
|
118 M | $ 1.23 | -3.15 % | $ 70.5 M | USA |
 |
Trevi Therapeutics
TRVI
|
1.51 B | $ 12.61 | -2.55 % | $ 1.7 B | USA |
 |
Taysha Gene Therapies
TSHA
|
1.46 B | $ 3.96 | -1.12 % | $ 1.27 B | USA |
 |
Kiromic BioPharma
KRBP
|
4.83 M | - | 6.61 % | $ 3.08 M | USA |
 |
Seelos Therapeutics
SEEL
|
5.44 M | - | -47.76 % | $ 6.27 M | USA |
 |
Theravance Biopharma
TBPH
|
742 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
UroGen Pharma Ltd.
URGN
|
924 M | $ 34.49 | -1.88 % | $ 1.66 B | Israel |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
23.6 B | $ 587.5 | 0.46 % | $ 26 B | USA |
 |
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | USA |
 |
Vericel Corporation
VCEL
|
1.88 B | $ 42.53 | -1.02 % | $ 2.14 B | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
123 M | - | - | $ 189 M | USA |
 |
Veracyte
VCYT
|
3.04 B | $ 47.93 | 4.11 % | $ 3.77 B | USA |
 |
VBI Vaccines
VBIV
|
9.65 M | - | -50.87 % | $ 1.09 M | USA |
 |
Vir Biotechnology
VIR
|
1.02 B | $ 10.57 | 1.34 % | $ 1.46 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | USA |
 |
Decibel Therapeutics
DBTX
|
102 M | - | - | $ 123 M | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.64 | 1.23 % | $ 13.1 M | USA |
 |
IVERIC bio
ISEE
|
2.97 B | - | - | $ 5.51 B | USA |
 |
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
358 M | $ 4.01 | -0.99 % | $ 236 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
66.7 M | $ 3.53 | -7.83 % | $ 37.6 M | USA |
 |
Viridian Therapeutics
VRDN
|
2.99 B | $ 22.37 | -1.97 % | $ 2.28 B | USA |
 |
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | USA |
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Molecular Templates
MTEM
|
10.1 M | - | -23.43 % | $ 495 K | USA |
 |
Verastem
VSTM
|
404 M | $ 10.04 | -0.2 % | $ 696 M | USA |
 |
VistaGen Therapeutics
VTGN
|
21.7 M | $ 0.18 | -3.9 % | $ 6.85 M | USA |
 |
vTv Therapeutics
VTVT
|
67.6 M | $ 25.55 | -5.93 % | $ 101 M | USA |
 |
Voyager Therapeutics
VYGR
|
241 M | $ 1.74 | -6.45 % | $ 102 M | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.64 | -2.06 % | $ 85.2 M | USA |
 |
CohBar
CWBR
|
5.31 M | - | -15.44 % | $ 2.2 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
1.2 B | - | - | $ 2.18 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
73.7 M | - | - | $ 105 M | USA |
 |
Global Blood Therapeutics
GBT
|
1.82 B | - | - | $ 4.62 B | USA |
 |
Idera Pharmaceuticals
IDRA
|
1.4 M | - | -23.04 % | $ 26.6 M | USA |
 |
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | USA |
 |
NanoString Technologies
NSTG
|
459 M | - | -37.43 % | $ 5.1 M | USA |